Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash from Financing Activities (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Cash from Financing Activities for 15 consecutive years, with -$6.3 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 126.92% to -$6.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.3 million through Dec 2025, up 5408.76% year-over-year, with the annual reading at $15.4 million for FY2025, 1323.69% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$6.3 million at Aytu Biopharma, down from $2.3 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $13.6 million in Q3 2022, with the low at -$6.3 million in Q4 2025.
  • Average Cash from Financing Activities over 5 years is $1.7 million, with a median of $911000.0 recorded in 2024.
  • The sharpest move saw Cash from Financing Activities tumbled 2090.48% in 2024, then soared 1116.57% in 2025.
  • Over 5 years, Cash from Financing Activities stood at $6.6 million in 2021, then plummeted by 128.3% to -$1.9 million in 2022, then surged by 93.24% to -$126000.0 in 2023, then crashed by 2090.48% to -$2.8 million in 2024, then tumbled by 126.92% to -$6.3 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$6.3 million, $2.3 million, and $13.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.